ZOCOR is an HMG-CoA reductase inhibitor indicated:
• To reduce the risk of total mortality by reducing risk of coronary
heart disease death, non-fatal myocardial infarction and stroke, and
the need for coronary and non-coronary revascularization
procedures in adults with established coronary heart disease,
cerebrovascular disease, peripheral vascular disease, and/or
diabetes, who are at high risk of coronary heart disease events.
• As an adjunct to diet to reduce low-density lipoprotein cholesterol
(LDL-C):
o In adults with primary hyperlipidemia.
o In adults and pediatric patients aged 10 years and older with
heterozygous familial hypercholesterolemia (HeFH).
• As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in
adults with homozygous familial hypercholesterolemia (HoFH).
• As an adjunct to diet for the treatment of adults with:
o Primary dysbetalipoproteinemia.
o Hypertriglyceridemia.
